Drugs facing NCE-1 in 2022

1. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(9 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(9 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(9 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(9 years from now)

US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant
Jun, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

2. List of Annovera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception

Dosage: RING;VAGINAL

More Information on Dosage

3. List of Arakoda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Biktarvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(10 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(10 years from now)

US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(a year ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(2 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(10 years from now)

US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(12 years from now)

US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
New Patient Population (NPP) Jun 18, 2022
M Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

5. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(6 years from now)

US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(9 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma with a braf mutation; Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma mediated by a b-raf protein kinase

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

6. List of Copiktra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(7 years from now)

USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982 SECURA Certain chemical entities, compositions and methods
Jan, 2029

(5 years from now)

US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(8 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

7. List of Daurismo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(7 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(5 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 21, 2023
Orphan Drug Exclusivity (ODE) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage

8. List of Delstrigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to the individual components of delstrigo; For the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's patent expiration?
More Information on Dosage

9. List of Doptelet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7638536 AKARX INC 2-Acylaminothiazole derivative or salt thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765764 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jan, 2023

(18 days ago)

US8338429 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jun, 2023

(4 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 21, 2023
Orphan Drug Exclusivity (ODE) Jun 26, 2026
New Indication (I) Jun 26, 2022

Drugs and Companies using AVATROMBOPAG MALEATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 21 May, 2018

Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

More Information on Dosage

10. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10195159 GW RES LTD Processes and apparatus for extraction of active substances and enriched extracts from natural products
May, 2022

(8 months ago)

US11096905 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11207292 GW RES LTD Cannabidiol preparations and its uses
Apr, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154516 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9949937 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956186 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10092525 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956183 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10111840 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10137095 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10603288 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709671 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709674 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956184 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956185 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10849860 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10966939 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709673 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11311498 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11357741 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11446258 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11400055 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11065209 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US10918608 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11406623 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

US11160795 GW RES LTD Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Mar, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with lennox-gastaut syndrome; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use for the treatment of atonic seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with dravet syndrome; Use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of focal seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with tuberous sclerosis complex; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; Use for reducing seizure frequency in patients with tuberous sclerosis complex; Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus; Use for the treatment of seizures associated with tuberous sclerosis complex

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

11. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(4 years from now)

US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

12. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(11 years from now)

US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

13. List of Galafold drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11304940 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11426396 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357764 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11376244 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357765 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9480682 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US10406143 AMICUS THERAP US Methods for treatment of fabry disease
May, 2027

(4 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9999618 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US10925866 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US11033538 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

US10525045 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(5 years from now)

USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US9095584 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US8592362 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US10813921 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Feb, 2029

(6 years from now)

US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(14 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
Mar, 2037

(14 years from now)

US11278540 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357762 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792279 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792278 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874656 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874655 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US10874657 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857142 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849889 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849890 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857141 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10471053 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10251873 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11357761 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10799491 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357763 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11389437 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11389436 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11278538 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278537 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278536 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278539 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11458128 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10806727 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11357784 AMICUS THERAP US Use of migalastat for treating Fabry disease in pregnant patients
Feb, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients; A method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

14. List of Lokelma drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's patent expiration?
More Information on Dosage

15. List of Lorbrena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(10 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 2, 2023
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage

16. List of Lutathera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 26, 2023
Orphan Drug Exclusivity (ODE) Jan 26, 2025

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

NCE-1 date: January, 2022

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

17. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(8 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(7 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(8 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(9 years from now)

US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(11 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(11 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(11 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(12 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(12 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV
Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV
Dec, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
New Patient Population (NPP) Apr 30, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Dosing Schedule (D) Sep 26, 2022
M Apr 10, 2023
Pediatric Exclusivity (PED) Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

More Information on Dosage

18. List of Mektovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(a month from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase; Treatment of melanoma with a braf mutation

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's patent expiration?
More Information on Dosage

19. List of Mulpleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 7 months from now)

US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(5 years from now)

US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Olumiant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Mar, 2029

(6 years from now)

US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(9 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(9 years from now)

US9737469 ELI LILLY AND CO Methods for treating hair loss disorders
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 10, 2025
New Chemical Entity Exclusivity (NCE) May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of rheumatoid arthritis; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo); Treatment of adult patients with severe alopecia areata

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's patent expiration?
More Information on Dosage

21. List of Omegaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(1 year, 9 months from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 27, 2023
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

22. List of Onpattro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(8 months from now)

US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(8 months from now)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations
Oct, 2027

(4 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(7 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

23. List of Oriahnn (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11459305 ABBVIE INC Processes for the preparation of uracil derivatives
Nov, 2028

(5 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

More Information on Dosage

24. List of Orilissa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 5 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(1 year, 5 months from now)

US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US10537572 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

US10682351 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's patent expiration?
More Information on Dosage

25. List of Pifeltro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; For use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed

Dosage: TABLET;ORAL

More Information on Dosage

26. List of Seysara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318706 ALMIRALL Substituted tetracycline compounds
May, 2031

(8 years from now)

US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Aug, 2028

(5 years from now)

US8513223 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders
Dec, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 1, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses; A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride; A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt; A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt

Dosage: TABLET;ORAL

More Information on Dosage

27. List of Symdeko (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Nov, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(10 years from now)

US10058546 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
Jul, 2033

(10 years from now)

US10206877 VERTEX PHARMS INC Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027
New Chemical Entity Exclusivity (NCE) Feb 12, 2023
New Patient Population (NPP) Jun 21, 2022

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 12 February, 2018

Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients age 6 years and older who have a r117h mutation in the cftr gene; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence; Treating cystic fibrosis patients ages 6 and older, who are homozygous for f508del or have at least 1 cftr gene mutation responsive to tezacaftor/ivacaftor, with tezacaftor and a solid composition comprising amorphous (<30% crystalline) ivacaftor; Treating cystic fibrosis patients ages 12 and older, who are homozygous for f508del or have at least 1 cftr gene mutation responsive to tezacaftor/ivacaftor, with tezacaftor and a solid composition comprising amorphous (<30% crystalline) ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older, who are homozygous for the f508del mutation or heterozygous for f508del and a second cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older, who are homozygous for the f508del mutation or heterozygous for f508del and a second cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients aged 12 and older, who are homozygous for the f508del mutation or have at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients aged 6 and older, who are homozygous for the f508del mutation or have at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; Treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; Treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; Treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive to tezacaftor/ivacaftor; Treatment of cystic fibrosis in patients 12 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->a, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s patent 10058546; Treatment of cystic fibrosis in patients 6 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s. patent 10058546; Treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Treatment of cf in patients 12 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, & 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; Treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; Treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; Treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; Treatment of cystic fibrosis in patients aged 6 years and older, who are homozygous for the f508del mutation or have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with an effective amount of tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older, who are homozygous for the f508del mutation or have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with an effective amount of tezacaftor and ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Talzenna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420650 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

US8012976 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Oct, 2029

(6 years from now)

US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(8 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 16, 2023

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 16 October, 2018

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer

Dosage: CAPSULE;ORAL

More Information on Dosage

29. List of Tavalisse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8211889 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(2 years from now)

US7538108 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Mar, 2026

(3 years from now)

US7989448 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8163902 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US7449458 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Sep, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48898 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(2 years from now)

US9266912 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(2 years from now)

US8912170 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US9283238 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8445485 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8652492 RIGEL PHARMS INC Wet granulation using a water sequestering agent
Nov, 2028

(5 years from now)

US8263122 RIGEL PHARMS INC Wet granulation using a water sequestering agent
Nov, 2030

(7 years from now)

US8771648 RIGEL PHARMS INC (Trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

US8951504 RIGEL PHARMS INC (trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2025
New Chemical Entity Exclusivity (NCE) Apr 17, 2023

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 17 April, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

How can I launch a generic of TAVALISSE before it's patent expiration?
More Information on Dosage

30. List of Tegsedi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(a month from now)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(7 months from now)

US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(2 years from now)

US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697860 AKCEA THERAPS Diagnosis and treatment of disease
Apr, 2031

(8 years from now)

US9399774 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 5, 2023
Orphan Drug Exclusivity (ODE) Oct 5, 2025

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

31. List of Tibsovo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850277 SERVIER Therapeutically active compositions and their methods of use
Jan, 2033

(9 years from now)

US9474779 SERVIER Therapeutically active compositions and their methods of use
Aug, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 SERVIER Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

US10717764 SERVIER Therapeutically active compounds and their methods of use
Jan, 2033

(9 years from now)

US9968595 SERVIER Pharmaceutical compositions of therapeutically active compounds
Mar, 2035

(12 years from now)

US10449184 SERVIER Pharmaceutical compositions of therapeutically active compounds
Mar, 2035

(12 years from now)

US10799490 SERVIER Pharmaceutical compositions of therapeutically active compounds
Mar, 2035

(12 years from now)

US10653710 SERVIER Combination therapy for treating malignancies
Oct, 2036

(13 years from now)

US10980788 SERVIER Therapy for treating malignancies
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023
Orphan Drug Exclusivity (ODE) Aug 25, 2028
New Indication (I) May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); Treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory; A method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidine; A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myelogenous leukemia (aml); A method of treating a cancer characterized by an idh1 mutation wherein the cancer is previously treated, locally advanced or metastatic cholangiocarcinoma

Dosage: TABLET;ORAL

How can I launch a generic of TIBSOVO before it's patent expiration?
More Information on Dosage

32. List of Tpoxx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8124643 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US9339466 SIGA TECHNOLOGIES Polymorphic forms of ST-246 and methods of preparation
Mar, 2031

(8 years from now)

CN101702904A SIGA TECHNOLOGIES Chemicals, Compositions, And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Aug, 2015

(7 years ago)

EP1638938A2 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

EP1638938A4 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

EP1638938B1 SIGA TECHNOLOGIES Compounds, Compositions And Methods For Treatment And Prevention Of Orthopoxvirus Infections And Associated Diseases
Jun, 2024

(1 year, 4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802714 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US8530509 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(1 year, 4 months from now)

US8039504 SIGA TECHNOLOGIES Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jul, 2027

(4 years from now)

US9907859 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(8 years from now)

US10576165 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(8 years from now)

US9233097 SIGA TECHNOLOGIES ST-246 liquid formulations
Aug, 2031

(8 years from now)

US7737168 SIGA TECHNOLOGIES Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 13, 2023

Drugs and Companies using TECOVIRIMAT ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 18 May, 2022

Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg; Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

33. List of Vitrakvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(6 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(14 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage

34. List of Vitrakvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(6 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient

Dosage: CAPSULE;ORAL

More Information on Dosage

35. List of Vizimpro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(2 years from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 27, 2025
New Chemical Entity Exclusivity (NCE) Sep 27, 2023

Drugs and Companies using DACOMITINIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation

Dosage: TABLET;ORAL

More Information on Dosage

36. List of Xofluza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(8 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative
Jun, 2030

(7 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative
May, 2031

(8 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US11306106 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 23 November, 2020

Treatment: Method for treating influenza; Method for post-exposure prophylaxis of influenza

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of XOFLUZA before it's patent expiration?
More Information on Dosage

37. List of Xospata drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound
Jul, 2030

(7 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Chemical Entity Exclusivity (NCE) Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET;ORAL

More Information on Dosage

38. List of Yupelri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7288657 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Dec, 2025

(2 years from now)

US9765028 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US10550081 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US8541451 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US11008289 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US11484531 MYLAN IRELAND LTD NA
Oct, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 9, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

How can I launch a generic of YUPELRI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in